Stockreport

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer RARITAN, N.J. Feb. 26, 2026 [Read more]